{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:00:29Z","timestamp":1768557629590,"version":"3.49.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03ZU1111CB and 03ZU1111JC"],"award-info":[{"award-number":["03ZU1111CB and 03ZU1111JC"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03ZU1111CB and 03ZU1111JC"],"award-info":[{"award-number":["03ZU1111CB and 03ZU1111JC"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-024-05993-y","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T15:02:23Z","timestamp":1730214143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma"],"prefix":"10.1007","volume":"150","author":[{"given":"Dominik","family":"Zolnowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Warncke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Pannach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Morgner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Ibach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"1","key":"5993_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosi\u00f1ol L, Ozet G et al (2020) A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 105(1):201\u2013208. https:\/\/doi.org\/10.3324\/haematol.2019.219295","journal-title":"Haematologica"},{"issue":"10297","key":"5993_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8","journal-title":"Lancet"},{"issue":"1","key":"5993_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","volume":"97","author":"L Besse","year":"2016","unstructured":"Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M et al (2016) Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 97(1):93\u2013100. https:\/\/doi.org\/10.1111\/ejh.12688","journal-title":"Eur J Haematol"},{"issue":"1","key":"5993_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M et al (2013) Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 161(1):87\u201394. https:\/\/doi.org\/10.1111\/bjh.12223","journal-title":"Br J Haematol"},{"issue":"6","key":"5993_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bjh.13384","volume":"169","author":"J Blad\u00e9","year":"2015","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L (2015) Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol 169(6):763\u2013765. https:\/\/doi.org\/10.1111\/bjh.13384","journal-title":"Br J Haematol"},{"issue":"3","key":"5993_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1600-0609.2011.01644.x","volume":"87","author":"JM Calvo-Villas","year":"2011","unstructured":"Calvo-Villas JM, Alegre A, Calle C, Hern\u00e1ndez MT, Garc\u00eda-S\u00e1nchez R, Ram\u00edrez G et al (2011) Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 87(3):281\u2013284. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01644.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"5993_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjh.12414","volume":"162","author":"CI Chen","year":"2013","unstructured":"Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH et al (2013) Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol 162(4):483\u2013488. https:\/\/doi.org\/10.1111\/bjh.12414","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"5993_CR8","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1182\/blood-2023-181331","volume":"142","author":"D Dima","year":"2023","unstructured":"Dima D, Davis JA, Rashid A, Rice M, DeJarnette S, Shune L et al (2023b) Outcomes of BCMA-directed chimeric antigen receptor T-cell (CART) therapy in patients with relapse-refractory multiple myeloma with extramedullary disease. Blood 142(Supplement 1):4882. https:\/\/doi.org\/10.1182\/blood-2023-181331","journal-title":"Blood"},{"issue":"3","key":"5993_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H et al (2024) Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transpl Cell Ther 30(3):308. e1-308.e13https:\/\/doi.org\/10.1016\/j.jtct.2023.12.016","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"5993_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/s1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337. https:\/\/doi.org\/10.1016\/s1470-2045(17)30578-8","journal-title":"Lancet Oncol"},{"issue":"9","key":"5993_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood.2020008209","volume":"137","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos M, Bringhen S, Anttila P, Capra M, Cavo M, Cole C et al (2021) Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood 137(9):1154\u20131165. https:\/\/doi.org\/10.1182\/blood.2020008209","journal-title":"Blood"},{"issue":"9","key":"5993_CR12","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"issue":"11","key":"5993_CR13","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N et al (2021) Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22(11):1582\u20131596. https:\/\/doi.org\/10.1016\/S1470-2045(21)00466-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"5993_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3324\/haematol.2017.178434","volume":"103","author":"N Gagelmann","year":"2018","unstructured":"Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM et al (2018) Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies Working Party of the EBMT. Haematologica 103(5):890\u2013897. https:\/\/doi.org\/10.3324\/haematol.2017.178434","journal-title":"Haematologica"},{"issue":"12","key":"5993_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M et al (2021) Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 22(12):1705\u20131720. https:\/\/doi.org\/10.1016\/S1470-2045(21)00535-0","journal-title":"Lancet Oncol"},{"issue":"11","key":"5993_CR16","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D et al (2022) German-speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 9(11):e810\u2013e821. https:\/\/doi.org\/10.1016\/S2352-3026(22)00263-0","journal-title":"Lancet Haematol"},{"issue":"11","key":"5993_CR17","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/jco.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A et al (2023) Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol 41(11):2087\u20132097. https:\/\/doi.org\/10.1200\/jco.22.01365","journal-title":"J Clin Oncol"},{"issue":"5","key":"5993_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749\u2013757","journal-title":"Br J Haematol"},{"issue":"9","key":"5993_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","volume":"12","author":"R Jim\u00e9nez-Segura","year":"2022","unstructured":"Jim\u00e9nez-Segura R, Rosi\u00f1ol L, Cibeira MT, Fern\u00e1ndez de Larrea C, Tovar N, Rodr\u00edguez-Lobato LG et al (2022) Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J 12(9):135. https:\/\/doi.org\/10.1038\/s41408-022-00730-5","journal-title":"Blood Cancer J"},{"issue":"6","key":"5993_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00277-019-03655-5","volume":"98","author":"M Jullien","year":"2019","unstructured":"Jullien M, Trudel S, Tessoulin B, Mah\u00e9 B, Dubruille V, Blin N et al (2019) Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Ann Hematol 98(6):1435\u20131440. https:\/\/doi.org\/10.1007\/s00277-019-03655-5","journal-title":"Ann Hematol"},{"issue":"9","key":"5993_CR21","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3109\/10428194.2015.1128542","volume":"57","author":"A Jurczyszyn","year":"2016","unstructured":"Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M et al (2016) Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma 57(9):2071\u20132076. https:\/\/doi.org\/10.3109\/10428194.2015.1128542","journal-title":"Leuk Lymphoma"},{"key":"5993_CR22","doi-asserted-by":"crossref","unstructured":"Krishnan A, Costa L, Schinke C, Karlin L, Morillo D, Martinez-Chamorro C et al Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in relapsed\/refractory multiple myeloma: efficacy and safety of patient subgroups from MonumenTAL-1. Poster presented at: 20th International Myeloma Society (IMS) Annual Meeting and Exposition; September 27\u201330, 2023; Athens, Greece","DOI":"10.1016\/S2152-2650(23)01641-5"},{"issue":"8","key":"5993_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"9","key":"5993_CR24","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"issue":"16suppl","key":"5993_CR25","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TH, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME et al (2023) CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol 41(16suppl):8009. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8009","journal-title":"J Clin Oncol"},{"issue":"13","key":"5993_CR26","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","volume":"126","author":"S Lonial","year":"2015","unstructured":"Lonial S, Boise LH, Kaufman J (2015a) How I treat high-risk myeloma. Blood 126(13):1536\u20131543. https:\/\/doi.org\/10.1182\/blood-2015-06-653261","journal-title":"Blood"},{"issue":"7","key":"5993_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/nejmoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al (2015b) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. https:\/\/doi.org\/10.1056\/nejmoa1505654","journal-title":"N Engl J Med"},{"issue":"1","key":"5993_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M et al (2017) The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol 96(1):73\u201380. https:\/\/doi.org\/10.1007\/s00277-016-2847-z","journal-title":"Ann Hematol"},{"issue":"5","key":"5993_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y et al (2023) Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol 18(5):667\u2013684. https:\/\/doi.org\/10.1007\/s11523-023-00989-z","journal-title":"Target Oncol"},{"issue":"1","key":"5993_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","volume":"105","author":"V Montefusco","year":"2020","unstructured":"Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R et al (2020) Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 105(1):193\u2013200. https:\/\/doi.org\/10.3324\/haematol.2019.219139","journal-title":"Haematologica"},{"issue":"17","key":"5993_CR31","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/nejmoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634. https:\/\/doi.org\/10.1056\/nejmoa1516282","journal-title":"N Engl J Med"},{"issue":"10192","key":"5993_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet Lond Engl 394(10192):29\u201338. https:\/\/doi.org\/10.1016\/s0140-6736(19)31240-1","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"5993_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/nejmoa2203478","journal-title":"N Engl J Med"},{"issue":"8","key":"5993_CR34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/nejmoa2024850","journal-title":"N Engl J Med"},{"key":"5993_CR35","doi-asserted-by":"publisher","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015) Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. ;33(26):2863-9. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","DOI":"10.1200\/JCO.2015.61.2267"},{"issue":"8","key":"5993_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/nejmoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766. https:\/\/doi.org\/10.1056\/nejmoa1606038","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"5993_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2023-177749","volume":"142","author":"D Pan","year":"2023","unstructured":"Pan D, Mouhieddine TH, Fu W, Moshier E, Parekh S, Jagannath S et al (2023) Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease. Blood 142(Supplement 1):1006. https:\/\/doi.org\/10.1182\/blood-2023-177749","journal-title":"Blood"},{"key":"5993_CR38","doi-asserted-by":"publisher","first-page":"S497","DOI":"10.1016\/S2152-2650(23)01449-0","volume":"23","author":"K Patel","year":"2023","unstructured":"Patel K, Rodr\u00edguez-Otero P, Manier S, Baz R, Raab MS, Cavo M et al (2023) MM-388 Idecabtagene Vicleucel (ide-cel) versus standard regimens in patients with triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in high-risk subgroups. Clin Lymphoma Myeloma Leuk 23:S497\u2013S498. https:\/\/doi.org\/10.1016\/S2152-2650(23)01449-0","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"5993_CR39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"M Pick","year":"2018","unstructured":"Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A et al (2018) Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur J Haematol 100(5):494\u2013501. https:\/\/doi.org\/10.1111\/ejh.13046","journal-title":"Eur J Haematol"},{"issue":"2","key":"5993_CR40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99(2):360\u2013364. https:\/\/doi.org\/10.3324\/haematol.2013.094409","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"5993_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-134319","volume":"136","author":"NS Raje","year":"2020","unstructured":"Raje NS, Siegel DS, Jagannath S, Lonial S, Munshi NC, Moreau P et al (2020) Idecabtagene Vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study. Blood 136(Supplement 1):37\u201338. https:\/\/doi.org\/10.1182\/blood-2020-134319","journal-title":"Blood"},{"issue":"12","key":"5993_CR42","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"7","key":"5993_CR43","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","volume":"91","author":"L Rasche","year":"2012","unstructured":"Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C et al (2012) Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol 91(7):1031\u20131037. https:\/\/doi.org\/10.1007\/s00277-012-1414-5","journal-title":"Ann Hematol"},{"issue":"7","key":"5993_CR44","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00277-014-2023-2","volume":"93","author":"L Rasche","year":"2014","unstructured":"Rasche L, Strifler S, Duell J, Rosenwald A, Buck A, Maeder U et al (2014) The lymphoma-like polychemotherapy regimen Dexa-BEAM in advanced and extramedullary multiple myeloma. Ann Hematol 93(7):1207\u20131214. https:\/\/doi.org\/10.1007\/s00277-014-2023-2","journal-title":"Ann Hematol"},{"issue":"11","key":"5993_CR45","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","volume":"22","author":"L Rasche","year":"2016","unstructured":"Rasche L, R\u00f6llig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU et al (2016) Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features. Biol Blood Marrow Transpl 22(11):1988\u20131996. https:\/\/doi.org\/10.1016\/j.bbmt.2016.08.024","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"5993_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A et al (2024) Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38(2):365\u2013371. https:\/\/doi.org\/10.1038\/s41375-024-02154-5","journal-title":"Leukemia"},{"issue":"11","key":"5993_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/nejmoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK et al (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388(11):1002\u20131014. https:\/\/doi.org\/10.1056\/nejmoa2213614","journal-title":"N Engl J Med"},{"issue":"5","key":"5993_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.0902-4441.2005.t01-1-ejh2462.x","volume":"76","author":"L Rosi\u00f1ol","year":"2006","unstructured":"Rosi\u00f1ol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blad\u00e9 J et al (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76(5):405\u2013408. https:\/\/doi.org\/10.1111\/j.0902-4441.2005.t01-1-ejh2462.x","journal-title":"Eur J Haematol"},{"issue":"3","key":"5993_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A et al (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 194(3):496\u2013507. https:\/\/doi.org\/10.1111\/bjh.17338","journal-title":"Br J Haematol"},{"issue":"11","key":"5993_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/s1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195\u20131206. https:\/\/doi.org\/10.1016\/s1470-2045(14)70440-1","journal-title":"Lancet Oncol"},{"key":"5993_CR51","doi-asserted-by":"crossref","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, Mateos MV et al (2023) Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). Poster presented at: American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL\/Virtual, June 2\u20136, 2023","DOI":"10.1097\/01.HS9.0000967676.59550.94"},{"issue":"4","key":"5993_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.clml.2014.12.007","volume":"15","author":"HJ Shin","year":"2015","unstructured":"Shin HJ, Kim K, Lee JJ, Song MK, Lee EY, Park SH et al (2015) The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. Clin Lymphoma Myeloma Leuk 15(4):227\u2013235. https:\/\/doi.org\/10.1016\/j.clml.2014.12.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"5993_CR53","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25(6):906\u2013908. https:\/\/doi.org\/10.1038\/leu.2011.29","journal-title":"Leukemia"},{"issue":"1","key":"5993_CR54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12885-021-08544-7","volume":"21","author":"MJ Sneyd","year":"2021","unstructured":"Sneyd MJ, Gray AR, Morison IM (2021) Trends in survival from myeloma, 1990\u20132015: a competing risks analysis. BMC Cancer 21(1):821. https:\/\/doi.org\/10.1186\/s12885-021-08544-7","journal-title":"BMC Cancer"},{"issue":"2","key":"5993_CR55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/nejmoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152. https:\/\/doi.org\/10.1056\/nejmoa1411321","journal-title":"N Engl J Med"},{"issue":"8","key":"5993_CR56","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971\u2013976. https:\/\/doi.org\/10.1182\/blood-2015-07-635383","journal-title":"Blood"},{"key":"5993_CR57","doi-asserted-by":"crossref","unstructured":"Touzeau C, Bahlis N, Maisel C, Karlin L, Varshavsky-Yanovsky AN, Leip E et al (2023) Efficacy and safety of elranatamab in patients with high-risk relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3. Poster presented at: European Hematology Association (EHA) Congress, Frankfurt, Germany, 8\u201311 June 2023","DOI":"10.1097\/01.HS9.0000970532.16622.f0"},{"issue":"11","key":"5993_CR58","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761\u20131767. https:\/\/doi.org\/10.3324\/haematol.2012.065698","journal-title":"Haematologica"},{"issue":"2","key":"5993_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol off J Eur Soc Med Oncol 21(2):325\u2013330. https:\/\/doi.org\/10.1093\/annonc\/mdp329","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"issue":"6","key":"5993_CR60","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J, Ghobrial IM, O\u2019Donnell EK, Weinstock M et al (2015) Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol 169(6):843\u2013850. https:\/\/doi.org\/10.1111\/bjh.13382","journal-title":"Br J Haematol"},{"issue":"6","key":"5993_CR61","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","volume":"54","author":"M Weinstock","year":"2013","unstructured":"Weinstock M, Ghobrial IM (2013) Extramedullary multiple myeloma. Leuk Lymphoma 54(6):1135\u20131141. https:\/\/doi.org\/10.3109\/10428194.2012.740562","journal-title":"Leuk Lymphoma"},{"key":"5993_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","volume":"18","author":"X Yin","year":"2018","unstructured":"Yin X, Tang L, Fan F, Jiang Q, Sun C, Hu Y (2018) Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. Cancer Cell Int 18:62. https:\/\/doi.org\/10.1186\/s12935-018-0553-8","journal-title":"Cancer Cell Int"},{"issue":"16","key":"5993_CR63","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"41","author":"WH Zhao","year":"2023","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J et al (2023) Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol 41(16):86. https:\/\/doi.org\/10.1186\/s13045-022-01301-8","journal-title":"J Hematol Oncol"},{"issue":"4","key":"5993_CR64","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/cancers12041035","volume":"12","author":"X Zhou","year":"2020","unstructured":"Zhou X, Fl\u00fcchter P, Nickel K, Meckel K, Messerschmidt J, B\u00f6ckle D et al (2020) Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease. Cancers (Basel) 12(4):1035. https:\/\/doi.org\/10.3390\/cancers12041035","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05993-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05993-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05993-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:07:11Z","timestamp":1730812031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05993-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5993"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05993-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional ethics committee of the institution (The State Chamber of Physicians of Saxony, EK-BR-118\/22\u2009\u2212\u20091).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was waived in accordance with the ethical approval due to retrospective design of the analysis and anonymization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}